Prediction of marker genes associated with hypertension by bioinformatics analyses

Gao,Yuan; Qi,Guo-Xian; Jia,Zhi-Mei; Sun,Ying-Xian

doi:10.3892/ijmm.2017.3000

Prediction of marker genes associated with hypertension by bioinformatics analyses

Authors:
- Yuan Gao
- Guo-Xian Qi
- Zhi-Mei Jia
- Ying-Xian Sun
View Affiliations

Affiliations: Department of Cardiology, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China
Published online on: May 25, 2017 https://doi.org/10.3892/ijmm.2017.3000
Pages: 137-145
Copyright: © Gao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

This study aimed to explore the underlying marker genes associated with hypertension by bioinformatics analyses. A gene expression profile (GSE54015) was downloaded. The differentially expressed genes (DEGs) between the normotensive female (NF) and hypertensive female (HF), and between the normotensive male (NM) and hypertensive male (HM) groups were analyzed. Gene Ontology (GO) and pathway enrichment analyses were performed, followed by protein-protein interaction (PPI) network construction. The transcription factors (TFs), and the common DEGs between the HF and HM groups were then analyzed. In total, 411 DEGs were identified between the HF and NF groups, and 418 DEGs were identified between the HM and NM groups. The upregulated DEGs in the HF and HM groups were enriched in 9 GO terms, including oxidation reduction, such as cytochrome P450, family 4, subfamily b, polypeptide 1 (Cyp4b1) and cytochrome P450, family 4, subfamily a, polypeptide 31 Cyp4a31). The downregulated DEGs were mainly enriched in GO terms related to hormone metabolic processes. In the PPI network, cytochrome P450, family 2, subfamily e, polypeptide 1 (Cyp2e1) had the highest degree in all 3 analysis methods in the HF group. Additionally, 4 TFs were indentified from the 2 groups of data, including sterol regulatory element binding transcription factor 1 (Srebf1), estrogen receptor 1 (Esr1), retinoid X receptor gamma (Rxrg) and peroxisome proliferator-activated receptor gamma (Pparg). The intersection genes were mainly enriched in GO terms related to the extracellular region. On the whole, our data indicate that the DEGs, Cyp4b1, Cyp4a31 and Loxl2, and the TFs, Esr1, Pparg and Rxrg, are associated with the progression of hypertension, and may thus serve as potential therapeutic targets in this disease.

View Figures

View References

1	Lupton SJ, Chiu CL and Lind JM: A hypertension gene: are we there yet? Twin Res Hum Genet. 14:295–304. 2011. View Article : Google Scholar : PubMed/NCBI
2	Chiu CL, Jackson KL, Hearn L, Steiner N, Head GA and Lind JM: Identification of genes with altered expression in male and female Schlager hypertensive mice. BMC Med Genet. 15:1012014. View Article : Google Scholar : PubMed/NCBI
3	Williams SS: Advances in genetic hypertension. Curr Opin Pediatr. 19:192–198. 2007. View Article : Google Scholar : PubMed/NCBI
4	Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, et al Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee: Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 42:1206–1252. 2003. View Article : Google Scholar : PubMed/NCBI
5	Mendis S, Puska P and Norrving B: Global atlas on cardiovascular disease prevention and control. World Health Organization; Geneva: 2011
6	Northcott CA, Glenn JP, Shade RE, Kammerer CM, Hinojosa-Laborde C, Fink GD, Haywood JR and Cox LA: A custom rat and baboon hypertension gene array to compare experimental models. Exp Biol Med (Maywood). 237:99–110. 2012. View Article : Google Scholar
7	Ehret GB, Munroe PB, Rice KM, Bochud M, Johnson AD, Chasman DI, Smith AV, Tobin MD, Verwoert GC, Hwang SJ, et al International Consortium for Blood Pressure Genome-Wide Association Studies; CARDIoGRAM consortium; CKDGen Consortium; KidneyGen Consortium; EchoGen consortium: CHARGE-HF consortium: Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature. 478:103–109. 2011. View Article : Google Scholar : PubMed/NCBI
8	Lifton RP, Gharavi AG and Geller DS: Molecular mechanisms of human hypertension. Cell. 104:545–556. 2001. View Article : Google Scholar : PubMed/NCBI
9	Machado RD, Eickelberg O, Elliott CG, Geraci MW, Hanaoka M, Loyd JE, Newman JH, Phillips JA III, Soubrier F, Trembath RC, et al: Genetics and genomics of pulmonary arterial hypertension. J Am Coll Cardiol. 54(Suppl 1): S32–S42. 2009. View Article : Google Scholar : PubMed/NCBI
10	Gooch JL and Sharma AC: Targeting the immune system to treat hypertension: where are we? Curr Opin Nephrol Hypertens. 23:473–479. 2014. View Article : Google Scholar : PubMed/NCBI
11	Austin ED, Ma L, LeDuc C, Berman Rosenzweig E, Borczuk A, Phillips JA III, Palomero T, Sumazin P, Kim HR, Talati MH, et al: Whole exome sequencing to identify a novel gene (caveolin-1) associated with human pulmonary arterial hypertension. Circ Cardiovasc Genet. 5:336–343. 2012. View Article : Google Scholar : PubMed/NCBI
12	Puig O, Wang I-M, Cheng P, Zhou P, Roy S, Cully D, Peters M, Benita Y, Thompson J and Cai TQ: Transcriptome profiling and network analysis of genetically hypertensive mice identifies potential pharmacological targets of hypertension. Physiol Genomics. 42A:24–32. 2010. View Article : Google Scholar : PubMed/NCBI
13	Carvalho BS and Irizarry RA: A framework for oligonucleotide microarray preprocessing. Bioinformatics. 26:2363–2367. 2010. View Article : Google Scholar : PubMed/NCBI
14	Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U and Speed TP: Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 4:249–264. 2003. View Article : Google Scholar : PubMed/NCBI
15	Smyth GK: Limma: linear models for microarray data. Bioinformatics and Computational Biology Solutions using R and Bioconductor. Gentleman R, Carey V, Huber W, Irizarry R and Dudoit S: Springer; New York: pp. 397–420. 2005, View Article : Google Scholar
16	Ferreira JA: The Benjamini-Hochberg method in the case of discrete test statistics. Int J Biostat. 3:112007. View Article : Google Scholar
17	Harris MA, Clark J, Ireland A, Lomax J, Ashburner M, Foulger R, Eilbeck K, Lewis S, Marshall B, Mungall C, et al: Gene Ontology Consortium: The Gene Ontology (GO) database and informatics resource. Nucleic Acids Res. 32:D258–D261. 2004. View Article : Google Scholar
18	Kanehisa M and Goto S: KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28:27–30. 2000. View Article : Google Scholar
19	Huang W, Sherman BT and Lempicki RA: Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 4:44–57. 2009. View Article : Google Scholar
20	Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller D, Huerta-Cepas J, Simonovic M, Roth A, Santos A, Tsafou KP, et al: STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 43:D447–D452. 2015. View Article : Google Scholar
21	Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B and Ideker T: Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 13:2498–2504. 2003. View Article : Google Scholar : PubMed/NCBI
22	Tang Y, Li M, Wang J, Pan Y and Wu FX: CytoNCA: a cytoscape plugin for centrality analysis and evaluation of protein interaction networks. Biosystems. 127:67–72. 2015. View Article : Google Scholar
23	Janky R, Verfaillie A, Imrichová H, Van de Sande B, Standaert L, Christiaens V, Hulselmans G, Herten K, Naval Sanchez M, Potier D, et al: iRegulon: from a gene list to a gene regulatory network using large motif and track collections. PLoS Comput Biol. 10:e10037312014. View Article : Google Scholar : PubMed/NCBI
24	Merico D, Isserlin R, Stueker O, Emili A and Bader GD: Enrichment map: a network-based method for gene-set enrichment visualization and interpretation. PLoS One. 5:e139842010. View Article : Google Scholar : PubMed/NCBI
25	Touyz RM: Reactive oxygen species in vascular biology: role in arterial hypertension. Expert Rev Cardiovasc Ther. 1:91–106. 2003. View Article : Google Scholar
26	Chabrashvili T, Tojo A, Onozato ML, Kitiyakara C, Quinn MT, Fujita T, Welch WJ and Wilcox CS: Expression and cellular localization of classic NADPH oxidase subunits in the spontaneously hypertensive rat kidney. Hypertension. 39:269–274. 2002. View Article : Google Scholar : PubMed/NCBI
27	Redón J, Oliva MR, Tormos C, Giner V, Chaves J, Iradi A and Sáez GT: Antioxidant activities and oxidative stress byproducts in human hypertension. Hypertension. 41:1096–1101. 2003. View Article : Google Scholar : PubMed/NCBI
28	Nelson DR and Nebert DW: Cytochrome P450 (CYP) gene superfamily. eLS. 2011. View Article : Google Scholar
29	Marji JS, Wang M-H and Laniado-Schwartzman M: Cytochrome P-450 4A isoform expression and 20-HETE synthesis in renal preglomerular arteries. Am J Physiol Renal Physiol. 283:F60–F67. 2002. View Article : Google Scholar : PubMed/NCBI
30	Singh H, Cheng J, Deng H, Kemp R, Ishizuka T, Nasjletti A and Schwartzman ML: Vascular cytochrome P450 4A expression and 20-hydroxyeicosatetraenoic acid synthesis contribute to endothelial dysfunction in androgen-induced hypertension. Hypertension. 50:123–129. 2007. View Article : Google Scholar : PubMed/NCBI
31	Sacerdoti D, Escalante B, Abraham NG, Mcgiff JC, Levere RD and Schwartzman ML: Treatment with tin prevents the development of hypertension in spontaneously hypertensive rats. Science. 243:388–390. 1989. View Article : Google Scholar : PubMed/NCBI
32	Kobayashi N, Ohno T, Yoshida K, Fukushima H, Mamada Y, Nomura M, Hirata H, Machida Y, Shinoda M, Suzuki N, et al: Cardioprotective mechanism of telmisartan via PPAR-γ-eNOS pathway in dahl salt-sensitive hypertensive rats. Am J Hypertens. 21:576–581. 2008. View Article : Google Scholar : PubMed/NCBI
33	Mendelsohn ME and Karas RH: The protective effects of estrogen on the cardiovascular system. N Engl J Med. 340:1801–1811. 1999. View Article : Google Scholar : PubMed/NCBI
34	Barrett-Connor E: Sex differences in coronary heart disease. Why are women so superior? The 1995 Ancel Keys Lecture. Circulation. 95:252–264. 1997. View Article : Google Scholar : PubMed/NCBI
35	Mendelsohn ME: Protective effects of estrogen on the cardiovascular system. Am J Cardiol. 89:12E–17E. 2002. View Article : Google Scholar : PubMed/NCBI
36	Kersten S, Desvergne B and Wahli W: Roles of PPARs in health and disease. Nature. 405:421–424. 2000. View Article : Google Scholar : PubMed/NCBI
37	Yilmaz-Aydogan H, Kurnaz O, Kurt O, Akadam-Teker B, Kucukhuseyin O, Tekeli A and Isbir T: Effects of the PPARG P12A and C161T gene variants on serum lipids in coronary heart disease patients with and without type 2 diabetes. Mol Cell Biochem. 358:355–363. 2011. View Article : Google Scholar : PubMed/NCBI
38	Matsuda Y, Hoshikawa Y, Ameshima S, Suzuki S, Okada Y, Tabata T, Sugawara T, Matsumura Y and Kondo T: Effects of peroxisome proliferator-activated receptor gamma ligands on monocrotaline-induced pulmonary hypertension in rats. Nihon Kokyuki Gakkai Zasshi. 43:283–288. 2005.In Japanese. PubMed/NCBI
39	Nohara A, Kawashiri M-A, Claudel T, Mizuno M, Tsuchida M, Takata M, Katsuda S, Miwa K, Inazu A, Kuipers F, et al: High frequency of a retinoid X receptor γ gene variant in familial combined hyperlipidemia that associates with atherogenic dyslipidemia. Arterioscler Thromb Vasc Biol. 27:923–928. 2007. View Article : Google Scholar : PubMed/NCBI
40	Sucov HM, Dyson E, Gumeringer CL, Price J, Chien KR and Evans RM: RXR alpha mutant mice establish a genetic basis for vitamin A signaling in heart morphogenesis. Genes Dev. 8:1007–1018. 1994. View Article : Google Scholar : PubMed/NCBI
41	Osorio JC, Stanley WC, Linke A, Castellari M, Diep QN, Panchal AR, Hintze TH, Lopaschuk GD and Recchia FA: Impaired myocardial fatty acid oxidation and reduced protein expression of retinoid X receptor-α in pacing-induced heart failure. Circulation. 106:606–612. 2002. View Article : Google Scholar : PubMed/NCBI
42	Rodríguez C, Martínez-González J, Raposo B, Alcudia JF, Guadall A and Badimon L: Regulation of lysyl oxidase in vascular cells: lysyl oxidase as a new player in cardiovascular diseases. Cardiovasc Res. 79:7–13. 2008. View Article : Google Scholar : PubMed/NCBI
43	Mäki JM, Räsänen J, Tikkanen H, Sormunen R, Mäkikallio K, Kivirikko KI and Soininen R: Inactivation of the lysyl oxidase gene Lox leads to aortic aneurysms, cardiovascular dysfunction, and perinatal death in mice. Circulation. 106:2503–2509. 2002. View Article : Google Scholar : PubMed/NCBI
44	Lucero HA and Kagan HM: Lysyl oxidase: an oxidative enzyme and effector of cell function. Cell Mol Life Sci. 63:2304–2316. 2006. View Article : Google Scholar : PubMed/NCBI
45	Sibon I, Sommer P, Lamaziere JM and Bonnet J: Lysyl oxidase deficiency: a new cause of human arterial dissection. Heart. 91:e33. 2005. View Article : Google Scholar : PubMed/NCBI
46	Nakashima Y and Sueishi K: Alteration of elastic architecture in the lathyritic rat aorta implies the pathogenesis of aortic dissecting aneurysm. Am J Pathol. 140:959–969. 1992.PubMed/NCBI